logo
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Yahoo08-04-2025

Topline Results Expected Q2 2025
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully enrolled participants across all three dose cohorts (0.25 mg, 0.50 mg and 1.0 mg of tacrolimus) at seven U.S. study sites. Topline results from the final cohort (1.0 mg) remain on track for the second quarter of 2025 and will represent the most comprehensive clinical dataset to date for LP-310.
'The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA-approved therapies,' said Dr. Michael Chancellor, Co-Founder and Chief Medical Officer of Lipella Pharmaceuticals. 'We have already observed encouraging safety and efficacy signals in the first two dose cohorts, including clinically meaningful reductions in pain, ulceration and inflammation. With the final cohort now fully enrolled, we look forward to reporting topline results in the near term and believe this dataset will be critical in informing next steps for development and broader clinical strategy.'
About the Phase 2a TrialThe Phase 2a trial is a multicenter, dose-ranging study designed to evaluate the safety, tolerability and preliminary efficacy of LP-310 in adult patients with symptomatic oral lichen planus. The trial consists of three dose levels (0.25 mg, 0.50 mg and 1.0 mg), administered as a twice-daily 10-milliliter oral rinse over four weeks. The study's primary objectives include assessing LP-310's safety profile and pharmacokinetics, while secondary endpoints evaluate its impact on pain, inflammation and oral ulceration using patient-reported and investigator-measured scoring systems.
About Oral Lichen Planus (OLP)OLP is a chronic, T-cell-mediated autoimmune disorder affecting the oral mucosa, often causing painful erosions, inflammation and ulcerative lesions. The condition impacts an estimated 6 million Americans, and there are currently no FDA-approved treatments available.
Next Steps in DevelopmentWith enrollment complete, Lipella remains on track to:
Report topline results from the 1.0 mg cohort in the first half of 2025
Submit an Investigational New Drug (IND) application for a Phase 2b trial in late 2025
Explore potential regulatory designations, including Breakthrough Therapy designation
About Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn.
Forward-Looking Statements This press release includes certain "forward-looking statements" which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, the current clinical trial results for LP-310 and our other products general capital market risks, our ability to regain and maintain compliance with the listing standards of The Nasdaq Stock Market LLC, regional, national or global political, economic, business, competitive, market and regulatory conditions, our current liquidity position and the need to obtain additional financing to support ongoing operations, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax or investment advice and should consult with your own advisors as to the matters described herein, as applicable.
CONTACT Jonathan Kaufman Chief Executive Officer Lipella Pharmaceuticals Inc. Info@Lipella.com1-412-894-1853
PCG Advisory Jeff Ramson jramson@pcgadvisory.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

KeyBanc Initiates Coverage of Zoom Communications (ZM) With Underweight Rating
KeyBanc Initiates Coverage of Zoom Communications (ZM) With Underweight Rating

Yahoo

time11 minutes ago

  • Yahoo

KeyBanc Initiates Coverage of Zoom Communications (ZM) With Underweight Rating

Zoom Communications Inc. (NASDAQ:ZM) is one of the 10 tech stocks on Wall Street's radar right now. On June 6, KeyBanc initiated coverage of Zoom Communications Inc. (NASDAQ:ZM) with an Underweight rating and set a $73 price target in a broader report on select Enterprise Software companies. The analyst noted that the company's core video conferencing business has faced challenges since the pandemic peak, as in-person work returned. The firm also mentioned the competitive pressure from Microsoft as it has strengthened its position with Teams, improving features and user experience. Keybanc said that the company's efforts to grow beyond video collaboration have not been very compelling. A close-up of a hand using a laptop to control an immersive video meeting. Similarly, on May 22, Wells Fargo increased its price target on Zoom Communications Inc. (NASDAQ:ZM) from $75 to $80 and maintained an Equal Weight rating on the stock. The stock was already trading around $2 above the analyst's price target on the day. Zoom (NASDAQ:ZM) provides an AI-driven work platform featuring video meetings, messaging, cloud phone systems, and productivity tools like whiteboards, workflow automation, and modular docs, while also supporting virtual events, contact centers, and third-party app integration across various industries. While we acknowledge the potential of ZM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

B.Riley Raises Price Target on Silicon Motion (SIMO), Maintains Buy Rating
B.Riley Raises Price Target on Silicon Motion (SIMO), Maintains Buy Rating

Yahoo

time11 minutes ago

  • Yahoo

B.Riley Raises Price Target on Silicon Motion (SIMO), Maintains Buy Rating

Silicon Motion Technology Corporation (NASDAQ:SIMO) is one of the . On June 5, increased its price target on Silicon Motion Technology Corporation (NASDAQ:SIMO) to $90 from $75 and reaffirmed its Buy rating on the stock. The firm pointed to the expanded Nvidia Bluefield DPU win and the upcoming Nintendo Switch 2 cycle as drivers of longer-term gains for the company. It further added that progress in the PCIe Gen5 PC and notebook market is on track, with Silicon Motion (NASDAQ:SIMO) projected to grow its market share to over 50% using its 8- and 4-channel products. Additionally, provided a bullish outlook on the company's future earnings as it said that similar momentum is expected from the adoption of UFS 4.0 in smartphones. The developments could push estimated earnings per share in 2026 and 2027 to around $5.25 and $6.50, respectively. An engineer in a lab coat tweaking a circuit board with intricate semiconductors. During the company's Q1 2025 earnings call, management highlighted that Silicon Motion (NASDAQ:SIMO) has partnered with NVIDIA for over a year to qualify its MonTitan server boot storage for the BlueField-3 DPU, a platform designed to optimize AI workloads and cloud networking. Starting later this year, its boot storage will support BlueField-3, creating new revenue and growth opportunities. Silicon Motion (NASDAQ:SIMO) designs and sells NAND flash controllers and specialized SSDs for various applications, including computing, enterprise data centers, mobile devices, and industrial uses, under multiple brand names. While we acknowledge the potential of SIMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Why Amazon Stock Still Looks Like a Long-Term Winner
Why Amazon Stock Still Looks Like a Long-Term Winner

Yahoo

time19 minutes ago

  • Yahoo

Why Amazon Stock Still Looks Like a Long-Term Winner

Amazon should register solid revenue gains in the years ahead, thanks to multiple tailwinds pushing it forward. AWS will continue to be a growth and profit engine for the business. With earnings set to keep rising, the current valuation looks compelling. 10 stocks we like better than Amazon › Amazon (NASDAQ: AMZN) has been one of the best investments anyone could've made. In the past 20 years, shares have catapulted 11,270% higher (as of June 3). A $10,000 investment would've turned into more than $1.1 million today. That's life-changing wealth. As of this writing, this "Magnificent Seven" stock trades 15% off its peak from early February. Now might be a great time to add this dominant enterprise to your portfolio. Here's why Amazon shares still look like a long-term winner. Investors prefer to own companies that exhibit solid growth, thanks to the presence of a powerful secular trend. Amazon stands out above the crowd because it has multiple tailwinds working to its benefit. We all know about the massive online marketplace, which makes Amazon a leader in the e-commerce niche of the broader retail sector. According to data from the Federal Reserve Bank of St. Louis, physical shopping in the U.S. still represents 84% of the industry, providing Amazon with a durable opportunity to capture in the decades ahead. Amazon Prime membership is estimated to have 220 million subscribers worldwide, providing recurring and predictable revenue for the business. People can buy items with fast and free delivery, get savings on gas, and watch shows and movies. Consequently, the rising popularity of streaming entertainment should make Prime a compelling service for more people. Advertising might fly under the radar, but that should change. In the first quarter, digital advertising contributed $13.9 billion to Amazon's revenue. That sales figure increased 19% year over year. counted 2.6 billion visitors in April, so there's plenty of attention that can be monetized. Amazon also has a budding presence within healthcare. Amazon One Medical is a primary care service offering in-person and telehealth appointments to patients. There's also Amazon Pharmacy, which can deliver medications at discounted prices. One important secular trend that hasn't been mentioned here yet is cloud computing, a market poised to register fantastic growth going forward. CEO Andy Jassy says that 85% of IT spending is still on-site, which introduces a truly massive opportunity as these companies shift to off-premises and take advantage of the cloud. Enter Amazon Web Services (AWS), which continues to be a significant growth engine, reporting a 17% revenue gain in Q1. In the past 12 months, AWS raked in a whopping $112 billion in sales, making it the leader in the global cloud market. It's also bolstering the bottom line. Operating income came in at $11.5 billion for AWS during Q1, translating to a remarkable operating margin of 39.5%. It has required substantial investments to get to this point, but now AWS can leverage its expense structure to generate sizable profits. With AWS, Amazon also has a critical platform to launch various artificial intelligence (AI) tools for its customers. "Generative AI is going to reinvent virtually every customer experience we know, and enable altogether new ones about which we've only fantasized," Jassy said. While Amazon certainly proves that it's a wonderful company, it's important for investors to look at the stock's valuation as well. If you pay too much, no matter how great a business it is, returns going forward can disappoint. Amazon shares trade at a forward price-to-earnings (P/E) ratio of 33.3. On the surface, this doesn't exactly look like a bargain. However, when you realize that net income soared 77% between 2021 and 2024, and that the analyst community sees earnings per share rising 62% from 2024 to 2027, it's easy to be bullish. Amazon has been a fantastic stock to own in the past, and it can still be a long-term winner in the future. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon. The Motley Fool has a disclosure policy. Why Amazon Stock Still Looks Like a Long-Term Winner was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store